BI 3011441

DRUG2 trials

Sponsors

Boehringer Ingelheim

Conditions

Solid Tumors, KRAS Mutation

Phase 1

A Study to Test Different Doses of BI 3011441 in Japanese People With Different Types of Advanced Cancer (NRAS/KRAS Mutation Positive)

CompletedNCT04742556

Boehringer IngelheimSolid Tumors, KRAS Mutation

Start: 2021-03-15End: 2022-10-20Updated: 2024-09-19

A Study to Find a Safe and Effective Dose of BI 1701963 Alone and in Combination With BI 3011441 in Patients With Advanced Cancer and a Certain Mutation (Kirsten Rat Sarcoma Viral Oncogene Homologue [KRAS])

TerminatedNCT04835714

Boehringer IngelheimSolid Tumors, KRAS Mutation

Start: 2021-04-20End: 2022-01-18Updated: 2023-02-01